VC-hosted peptide event spotlights push for US-based peptide manufacturing
Three Gen Z venture capitalists hosted a black-tie peptide event aboard the historic SS Jeremiah O'Brien ship in San Francisco, drawing roughly 150 attendees. Guests sampled a topical GHK-Cu cream and three sublingual peptide strips from startup Afterglow, with organizers using the WWII vessel as a symbol for American industrial capability and arguing the pharmaceutical supply chain should be based domestically. The event coincided with a recent interim policy from the Department of Health and Human Services allowing certain unapproved peptides to be used in compounding, a decision that FDA career scientists have not endorsed.
GoKawiil's interpretation of the reporting above, not reported fact.
The gathering reflects growing investor interest in peptides, a category that has largely operated in a gray market with limited oversight on sourcing and manufacturing. The HHS policy shift could reshape how peptides reach consumers by bypassing standard clinical trials, which some industry experts warn undermines established safety and efficacy testing. This suggests a broader tension between venture-backed enthusiasm for unproven wellness products and regulatory caution rooted in insufficient scientific evidence.
- A black-tie peptide event aboard a WWII ship drew 150 attendees and was organized by three Gen Z VCs advocating for US-based peptide production.
- HHS's interim policy permits certain unapproved peptides for compounding, despite FDA scientists stating insufficient safety and efficacy evidence at a July hearing.
- Industry experts warn the policy could weaken the clinical trial framework that traditionally governs pharmaceutical safety standards.
Source: theverge.com — Victoria Song, 2026-11-12
Published there as: “Meet the people who want peptides to be made in America”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.